CAS NO: | 66515-29-5 |
包装 | 价格(元) |
10 mM * 1 mL in Water | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
生物活性 | MSOP is a selectivegroup III metabotropic glutamate receptorantagonist with apparentKDof 51 μM for the L-AP4-sensitive presynapticmGluR. | ||||||||||||||||
IC50& Target | KD: 51 μM (L-AP4-sensitive presynaptic mGluR)[1]. | ||||||||||||||||
体外研究 (In Vitro) | In the presence of 200 μM MSOP, a rightward parallel shift of the dose-response curve to L-AP4 is observed, with an apparent KDcalculated as 51±6 μM (n=3). MSOP is shown to be selective for the L-APC sensitive presynaptic mGluR, the apparent KDfor the interaction of MSOP with the (1S, 3S)-ACPD sensitive receptor calculated as greater than 700 μM (n=3)[1]. | ||||||||||||||||
体内研究 (In Vivo) | It is found that TBOA-induced antinociceptive effects are significantly blocked by intrathecal co-administration of MSOP (second phase of formalin model: F3,16=30.96, P<0.001; CFA model: F3,16=30.77, P<0.001). As expected, intrathecal TBOA (10 μg) reduces the number of formalin-induced flinches and shakes by 47% of the value in the saline-treated group in the second phase (P<0.001) and blocked the CFA-induced decrease in ipsilateral paw withdrawal latency by 60% of the value in the saline-treated group (P=0.01). The number of formalin-induced flinches in the second phase in the group treated with MSOP and TBOA is increased by 56% (P=0.04) of the value in the TBOA-treated group. CFA-induced paw withdrawal latency in the group treated with MSOP and TBOA is decreased by 86% (P=0.03) of the value in the TBOA-treated group[2]. | ||||||||||||||||
分子量 | 199.10 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C4H10NO6P | ||||||||||||||||
CAS 号 | 66515-29-5 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: H2O : 19 mg/mL(95.43 mM;Need ultrasonic and warming) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |